Buoyed by data from a trial of its T-cell engager (TCE) therapy in prostate cancer that almost tripled its share price, Janux Therapeutics has moved quickly to file a stoc
Shares in Minerva Neurosciences have lost more than half their value after the FDA rejected its marketing application for roluperidone as a treatment for the negative symp
The FDA has approved Allecra Therapeutics' Exblifep, a combination antibiotic for complicated urinary tract infections (cUTIs) that will now launch later this year, but tu
Southampton, UK-based start-up Curve Therapeutics has completed a £40.5 million ($51 million) in Series A financing for its drug discovery platform that enables drug scree
Big pharma’s interest in using protein degradation as a therapeutic strategy shows no sign of abating, as Novo Nordisk signs a wide-ranging deal with US biotech Neomorph t
The industry has been calling for a disease-agnostic event fully dedicated to the exciting new modality of peptide-based drugs.
A brand-new event has just launched in the renowned World ADC Series – the inaugural ADC Payload Summit is taking place
According to the FDA, 2024 will be the ’breakout year’ for gene therapies.
In the dynamic cell therapy landscape, where financial challenges continue to prevail, the emphasis on innovative process development becomes pivotal.